Merck & Co has announced FDA approval for Keytruda (pembrolizumab) combined with chemotherapy for first-line treatment of ...

Merck & Co. Inc. said Wednesday the U.S. Food and Drug Administration has approved its blockbuster cancer drug Keytruda as a treatment for malignant plural mesothelioma, a rare cancer associated ...

The FDA has approved Keytruda in combination with pemetrexed and platinum chemotherapy, as first-line Tx of unresectable advanced or metastatic malignant pleural mesothelioma.

As ever, US pharma giant Merck & Co has been sharing plenty of data on its blockbuster anti-PD-1 therapy Keytruda ...

Merck & Co., Inc. MRK announced that the FDA had approved its blockbuster anti-PD-1 therapy, Keytruda (pembrolizumab), for a new indication. The regulatory body has now approved Keytruda in ...

South Korea’s Celltrion has started work on a biosimilar version of pembrolizumab, Merck & Co’s blockbuster immunotherapy Keytruda ... of a superior data package, including stability data ...

The company's immunotherapy Keytruda recorded $7.27 billion in revenue ... in the U.S. but hampered by lower sales in China due to shipment timing. "As we learn more, we will assess future ...

Merck's bumpy six-year relationship with Eisai's anti-cancer medication Lenvima landed on somewhat better footing in Spain ...

Litchfield said that if Zhifei’s shipments to points of vaccination in China don’t increase, Merck will likely ship fewer doses ... of the patents that protect Keytruda, its cancer ...

In the completed Phase 1/2a clinical trial (NCT03715985), assessing EVX-01 in combination with a PD-1 inhibitor, eight of twelve metastatic melanoma patients (67%) had objective clinical responses ...

The company (MRK) said the approval is the first for Keytruda to treat MPM in the U.S. and is in combination with pemetrexed and platinum chemotherapy. MPM is a rare and aggressive malignancy ...

The combination statistically significantly improved overall survival, reducing the risk of death by 21% compared with chemotherapy alone. The Food and Drug Administration (FDA) has approved ...